Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20340664 | 0.91 | POLB (0.47) | L3MBTL1POLBTSHRLMNAHPGD | |
| SCHEMBL19182655 | 0.90 | L3MBTL1 (0.48) | L3MBTL1POLBTSHRLMNAHPGD | |
| SCHEMBL20374788 | 0.89 | POLB (0.46) | L3MBTL1POLBTSHRLMNAHPGD | |
| SCHEMBL23119558 | 0.88 | POLB (0.47) | L3MBTL1POLBTSHRLMNAHPGD | |
| SCHEMBL19261359 | 0.86 | POLB (0.49) | L3MBTL1POLBTSHRLMNAHPGD | |
| SCHEMBL22199660 | 0.84 | POLB (0.49) | L3MBTL1POLBTSHRLMNAHPGD | |
| SCHEMBL19200319 | 0.83 | TSHR (0.49) | L3MBTL1POLBTSHRLMNAHPGD | |
| SCHEMBL19645192 | 0.83 | POLB (0.48) | L3MBTL1POLBTSHRLMNAHPGD | |
| SCHEMBL19618148 | 0.80 | POLB (0.53) | L3MBTL1POLBTSHRLMNAALDH1A1 | |
| SCHEMBL8379974 | 0.80 | L3MBTL1 (0.48) | L3MBTL1POLBTSHRLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | PDK1, PDK3, PDK2 | L3MBTL1 1562/4885POLB 844/4885TSHR 3492/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | L3MBTL1 3969/4885POLB 313/4885TSHR 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.